Sangamo’s Fabry therapy partner search looks futile, and Geoff Porges is back

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.

This is the online version of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.

My favorite Robert Redford movies: “The Sting” and “All the President’s Men.” (Of course, the latter.)

Why Sangamo is facing an uphill challenge

Sangamo Therapeutics hasn’t convinced a pharma company to buy its experimental gene therapy for Fabry disease after two years of trying. Here’s why a deal may never happen: